ZA200603234B - Novel crystalline forms of {2-[1-(3,5-bis-trifluoromethyul-benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-[2-chlorophenyl)-methanone - Google Patents
Novel crystalline forms of {2-[1-(3,5-bis-trifluoromethyul-benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-[2-chlorophenyl)-methanone Download PDFInfo
- Publication number
- ZA200603234B ZA200603234B ZA200603234A ZA200603234A ZA200603234B ZA 200603234 B ZA200603234 B ZA 200603234B ZA 200603234 A ZA200603234 A ZA 200603234A ZA 200603234 A ZA200603234 A ZA 200603234A ZA 200603234 B ZA200603234 B ZA 200603234B
- Authority
- ZA
- South Africa
- Prior art keywords
- pyridin
- chlorophenyl
- methanone
- triazol
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/46—Oxygen atoms
- C07D213/50—Ketonic radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51430003P | 2003-10-24 | 2003-10-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200603234B true ZA200603234B (en) | 2007-07-25 |
Family
ID=34549327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200603234A ZA200603234B (en) | 2003-10-24 | 2006-04-21 | Novel crystalline forms of {2-[1-(3,5-bis-trifluoromethyul-benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-[2-chlorophenyl)-methanone |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US7381826B2 (enExample) |
| JP (1) | JP4959336B2 (enExample) |
| KR (1) | KR100848407B1 (enExample) |
| CN (1) | CN1863791B (enExample) |
| AR (1) | AR046131A1 (enExample) |
| AT (1) | ATE462700T1 (enExample) |
| AU (1) | AU2004285855B8 (enExample) |
| BR (1) | BRPI0415010B8 (enExample) |
| CA (1) | CA2542140C (enExample) |
| CL (2) | CL2009001310A1 (enExample) |
| CR (1) | CR8353A (enExample) |
| DE (1) | DE602004026333D1 (enExample) |
| DK (1) | DK1675846T3 (enExample) |
| EA (1) | EA008881B1 (enExample) |
| EC (1) | ECSP066517A (enExample) |
| ES (1) | ES2340772T3 (enExample) |
| HR (1) | HRP20100207T1 (enExample) |
| IL (1) | IL174926A0 (enExample) |
| MA (1) | MA28329A1 (enExample) |
| MY (1) | MY157375A (enExample) |
| NO (1) | NO335090B1 (enExample) |
| NZ (2) | NZ580480A (enExample) |
| PE (1) | PE20050481A1 (enExample) |
| PT (1) | PT1675846E (enExample) |
| TW (1) | TW200524906A (enExample) |
| UA (1) | UA82901C2 (enExample) |
| WO (1) | WO2005042515A1 (enExample) |
| ZA (1) | ZA200603234B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2121610B1 (en) * | 2006-12-20 | 2014-04-02 | Eli Lilly & Company | Novel intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone |
| WO2009075778A2 (en) * | 2007-12-06 | 2009-06-18 | The Regents Of The University Of California | Nonpeptidic inhibitors of cruzain |
| US8080568B1 (en) * | 2010-06-29 | 2011-12-20 | Ewha University - Industry Collaboration Foundation | 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors |
| KR20170122777A (ko) | 2015-03-04 | 2017-11-06 | 반다 파마슈티칼즈, 인코퍼레이티드. | 트라디피턴트에 의한 치료 방법 |
| US10287287B2 (en) | 2015-08-17 | 2019-05-14 | Eli Lilly And Company | Process development of a pyridine-containing NK-1 receptor antagonist |
| KR20200054232A (ko) | 2017-09-13 | 2020-05-19 | 반다 파마슈티칼즈, 인코퍼레이티드. | 트라디피탄트를 이용한 아토피 피부염의 개선된 치료 |
| KR20250140655A (ko) * | 2017-11-17 | 2025-09-25 | 반다 파마슈티칼즈, 인코퍼레이티드. | 트라디피탄트를 이용한 위장 질환의 치료 방법 |
| US20210228555A1 (en) | 2018-06-08 | 2021-07-29 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
| US10821099B2 (en) | 2018-09-28 | 2020-11-03 | Vanda Pharmaceuticals Inc. | Use of tradipitant in motion sickness |
| CN111918701B (zh) | 2018-09-28 | 2024-08-02 | 万达制药公司 | 曲地匹坦在晕动病中的用途 |
| WO2020117811A1 (en) * | 2018-12-03 | 2020-06-11 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
| WO2021173641A1 (en) | 2020-02-25 | 2021-09-02 | Vanda Pharmaceuticals Inc. | Improved treatment of atopic dermatitis with tradipitant |
| WO2021195205A1 (en) | 2020-03-26 | 2021-09-30 | Vanda Pharmaceuticals Inc. | Treatment of lower respiratory tract infection with tradipitant |
| WO2023019084A1 (en) | 2021-08-12 | 2023-02-16 | Vanda Pharmaceuticals Inc. | Treatment of gastric accommodation with tradipitant |
| US20240350469A1 (en) | 2021-08-31 | 2024-10-24 | Vanda Pharmaceuticals Inc. | Treatment of lower respiratory tract infection with tradipitant |
| WO2024138040A1 (en) | 2022-12-21 | 2024-06-27 | Vanda Pharmaceuticals Inc. | Methods of treatment with tradipitant |
| US20250255855A1 (en) | 2024-02-09 | 2025-08-14 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020099067A1 (en) | 1993-07-08 | 2002-07-25 | Ulrich Posanski | Pharmaceutical compositions for sparingly soluble therapeutic agents |
| GB9505492D0 (en) * | 1995-03-18 | 1995-05-03 | Merck Sharp & Dohme | Therapeutic agents |
| GB9525296D0 (en) * | 1995-12-11 | 1996-02-07 | Merck Sharp & Dohme | Therapeutic agents |
| JP2001502311A (ja) * | 1996-10-07 | 2001-02-20 | メルク シヤープ エンド ドーム リミテツド | 抗鬱及び／又は抗不安薬としてのｃｎｓ浸透性ｎｋ―１受容体拮抗薬 |
| AR032130A1 (es) * | 1999-08-13 | 2003-10-29 | Vertex Pharma | Un compuesto inhibidor de quinasas proteicas, una composicion farmaceutica que lo incluye, y un metodo para tratar afecciones con dicho compuesto |
| EP1228068A1 (en) * | 1999-10-29 | 2002-08-07 | Merck & Co., Inc. | Polymorphic form of a tachykinin receptor antagonist |
| US20020044971A1 (en) | 2000-07-07 | 2002-04-18 | Amidon Gordon L. | Dissolution rate of poorly soluble drugs |
| JP4559087B2 (ja) * | 2002-04-26 | 2010-10-06 | イーライ リリー アンド カンパニー | タキキニン受容体アンタゴニストとしてのトリアゾール誘導体 |
-
2004
- 2004-10-12 BR BRPI0415010A patent/BRPI0415010B8/pt active IP Right Grant
- 2004-10-12 US US10/574,712 patent/US7381826B2/en not_active Expired - Lifetime
- 2004-10-12 DK DK04793893.1T patent/DK1675846T3/da active
- 2004-10-12 DE DE602004026333T patent/DE602004026333D1/de not_active Expired - Lifetime
- 2004-10-12 AT AT04793893T patent/ATE462700T1/de active
- 2004-10-12 HR HR20100207T patent/HRP20100207T1/hr unknown
- 2004-10-12 EA EA200600829A patent/EA008881B1/ru not_active IP Right Cessation
- 2004-10-12 PT PT04793893T patent/PT1675846E/pt unknown
- 2004-10-12 AU AU2004285855A patent/AU2004285855B8/en not_active Expired
- 2004-10-12 CA CA2542140A patent/CA2542140C/en not_active Expired - Lifetime
- 2004-10-12 CN CN2004800291393A patent/CN1863791B/zh not_active Expired - Lifetime
- 2004-10-12 JP JP2006536635A patent/JP4959336B2/ja not_active Expired - Lifetime
- 2004-10-12 ES ES04793893T patent/ES2340772T3/es not_active Expired - Lifetime
- 2004-10-12 KR KR1020067007751A patent/KR100848407B1/ko not_active Expired - Lifetime
- 2004-10-12 WO PCT/US2004/030914 patent/WO2005042515A1/en not_active Ceased
- 2004-10-12 NZ NZ580480A patent/NZ580480A/en unknown
- 2004-10-12 NZ NZ545917A patent/NZ545917A/en unknown
- 2004-10-20 AR ARP040103801A patent/AR046131A1/es not_active Application Discontinuation
- 2004-10-20 PE PE2004001008A patent/PE20050481A1/es not_active Application Discontinuation
- 2004-10-21 MY MYPI20044338A patent/MY157375A/en unknown
- 2004-10-22 TW TW093132097A patent/TW200524906A/zh unknown
- 2004-12-10 UA UAA200604473A patent/UA82901C2/uk unknown
-
2006
- 2006-04-11 IL IL174926A patent/IL174926A0/en unknown
- 2006-04-21 CR CR8353A patent/CR8353A/es not_active Application Discontinuation
- 2006-04-21 ZA ZA200603234A patent/ZA200603234B/en unknown
- 2006-04-21 EC EC2006006517A patent/ECSP066517A/es unknown
- 2006-05-22 MA MA29043A patent/MA28329A1/fr unknown
- 2006-05-24 NO NO20062371A patent/NO335090B1/no unknown
-
2009
- 2009-05-29 CL CL2009001310A patent/CL2009001310A1/es unknown
- 2009-05-29 CL CL2009001311A patent/CL2009001311A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200603234B (en) | Novel crystalline forms of {2-[1-(3,5-bis-trifluoromethyul-benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-[2-chlorophenyl)-methanone | |
| WO1994010167A1 (en) | Tachykinin antagonists | |
| RS20060318A (sr) | Derivati n-/fenil(alkil-piperidin-2-il)metil/benzamida postupak za njihovo dobijanje i njihova terapeutska primena | |
| EP3243819A1 (en) | New crystal form of neratinib maleate and preparation method therefor | |
| SK6112003A3 (en) | Amidoalkyl-piperidine and amidoalkyl-piperazine derivatives for the treatment of nervous system disorders | |
| WO2016131431A1 (en) | Solid forms of empagliflozin | |
| WO2023087611A1 (zh) | 一类依巴斯汀的盐及其制备方法和应用 | |
| CZ180898A3 (cs) | Způsob a meziprodukty pro výrobu 1-benzyl-4-((5,6-dimethoxy-1-indanon)-2-yl)methylpiperidinu | |
| AU2024267706A1 (en) | Crystal form of lipoprotein compound and preparation method therefor | |
| CN114456150A (zh) | Nr2b受体拮抗剂或其可药用的盐、制备方法及用途 | |
| JP2019517494A (ja) | 腎髄質外層カリウムチャネル阻害剤としての医薬的に許容される塩 | |
| NO171362B (no) | Analogifremgangsmaate for fremstilling av nye aralkylaminforbindelser og deres salter | |
| AU2023285191A1 (en) | Pharmaceutically acceptable salt of benzo[c]chroman compound and polymorphic form and use of pharmaceutically acceptable salt | |
| EP1379234A1 (en) | Halogenated aminobenzophenones and aminobenzoylpyridines as inhibitors of il-1 and tnf | |
| SK5282002A3 (en) | Phenyl- and pyridyl-tetrahydro-pyridines having tnf inhibiting activity | |
| WO2018103663A1 (zh) | 一种取代的吡嗪甲酰胺类化合物及包含该化合物的组合物及其用途 | |
| WO2004099142A1 (en) | Hydrobromide salt of benzyl-piperidylmethyl-indanone and its polymorphs | |
| EP1675846B1 (en) | Novel crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1h- [1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone | |
| US20220235030A1 (en) | Selective histamine h3 antagonist acid addition salts and process for the preparation thereof | |
| CN120607535A (zh) | 一种kif18a抑制剂的可药用盐、晶型及其制备方法和应用 | |
| EP3256477A1 (en) | Solid forms of dolutegravir salts and a method of their preparation | |
| JP2025505801A (ja) | 窒素含有複素環化合物の結晶、製造方法及び使用 | |
| HK40063558A (en) | Pharmaceutical salts of benzothiazol compounds, polymorphs and methods for preparation thereof | |
| CN113631554A (zh) | 苯并噻唑化合物的药用盐、多晶型物及其制备方法 | |
| EP2154137A1 (en) | Crystalline form of moxifloxacin base |